ProShares Ultra NASDAQ Biotechnology
BIB
BIB
24 hedge funds and large institutions have $5.59M invested in ProShares Ultra NASDAQ Biotechnology in 2022 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 9 closing their positions.
New
Increased
Maintained
Reduced
Closed
more ownership
Funds ownership: →
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
34% less call options, than puts
Call options by funds: $1.57M | Put options by funds: $2.38M
44% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 9
Holders
24
Holding in Top 10
–
Calls
$1.57M
Puts
$2.38M
Top Buyers
| 1 | +$1.6M | |
| 2 | +$680K | |
| 3 | +$290K | |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$19K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$12K |
Top Sellers
| 1 | -$670K | |
| 2 | -$515K | |
| 3 | -$444K | |
| 4 |
TCM
Traynor Capital Management
Malvern,
Pennsylvania
|
-$298K |
| 5 |
Koshinski Asset Management
Decatur,
Illinois
|
-$276K |